Login / Signup

Severe acquired hypertriglyceridemia following COVID-19.

Lauré M FijenAldo GrefhorstJohannes H M LevelsDanny M Cohn
Published in: BMJ case reports (2021)
Severe hypertriglyceridemia is a major risk factor for acute pancreatitis. In exceptional cases, it is caused by plasma components inhibiting lipoprotein lipase activity. This phenomenon is predominantly associated with autoimmune diseases. Here, we report a case of severe hypertriglyceridemia due to a transient reduction in lipoprotein lipase activity following an episode of COVID-19 in an otherwise healthy 45-year-old woman. The lipoprotein lipase activity of the patient was markedly reduced compared with a healthy control and did recover to 20% of the healthy control's lipoprotein lipase activity 5 months after the COVID-19 episode. Mixing tests substantiated reduced lipolytic capacity in the presence of the patient's plasma at presentation compared with a homozygous lipoprotein lipase-deficient control, which was no longer present at follow-up. Western blotting confirmed that the quantity of lipoprotein lipase was not aberrant. Fibrate treatment and a strict hypolipidemic diet improved the patient's symptoms and triglyceride levels.
Keyphrases
  • coronavirus disease
  • low density lipoprotein
  • case report
  • sars cov
  • early onset
  • physical activity
  • south africa
  • respiratory syndrome coronavirus
  • signaling pathway
  • depressive symptoms
  • brain injury
  • replacement therapy